---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-22-000049"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:25:35.536706+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna Q3 net income $1.0B, EPS $2.53; lowers 2022 sales view to $18-19B

## Summary
- Q3 revenue $3.4B (down 32% YoY), GAAP net income $1.0B, diluted EPS $2.53 (down 67%).
- Product sales $3.1B, down 35%; cost of sales 35% including $333M write-downs and $209M unutilized capacity.
- 2022 sales guidance lowered to $18-19B ($2-3B deferred to 2023); 2023 preliminary APAs $4.5-5.5B.
- Completed $3B buyback; new $3B program underway; cash $17.0B.
- Pipeline: PCV Phase 2 data Q4 2022; RSV Phase 3 data this winter; flu Phase 3 data Q1 2023; $250M from Merck.

## SEC filing metadata
- accession: 0001682852-22-000049
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000049/0001682852-22-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000049/mrna-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-22-000049
- JSON: https://secwatch.observer/filing/0001682852-22-000049.json
- Plain text: https://secwatch.observer/filing/0001682852-22-000049.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported third quarter ended September 30, 2022 results: revenue $3.4 billion, net income $1.0 billion, EPS $2.53. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Revenue: $3.4 billion
  - Net income: $1.0 billion
  - EPS: $2.53
  - Guidance: reaffirmed
  - Result: reported results
  source text: Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates Third quarter 2022 revenues of $3.4 billion ; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000049/0001682852-22-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.